Semaglutide is a synthetic GLP-1 receptor agonist — a peptide therapeutic structurally based on the native glucagon-like peptide 1 (GLP-1) hormone with amino-acid substitutions and a fatty-acid sidechain that extend the half-life to support once-weekly subcutaneous administration. Studied across type 2 diabetes, obesity, and cardiovascular-outcome clinical trial programs (SUSTAIN, STEP, SELECT).
Definition
Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk. The molecule is structurally based on native GLP-1(7-37) with substitution of alanine at position 8 (the canonical DPP-IV cleavage site, replaced with aminoisobutyric acid) for protease resistance, a substitution at position 34, and attachment of a C18 fatty-acid sidechain via a spacer that mediates non-covalent reversible binding to serum albumin. The albumin-binding sidechain is the engineering feature that drives the long plasma half-life (~165 hours) supporting once-weekly subcutaneous dosing.
The compound is FDA-approved across multiple indications: type 2 diabetes (subcutaneous and oral formulations), chronic weight management in adults with obesity, and reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Active GLP-1 receptor engagement drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central nervous system effects on appetite and energy intake.
How semaglutide is studied in research and clinical literature
The semaglutide clinical-trial program is one of the most extensively published peptide-therapeutic literatures of the past decade. The SUSTAIN program established subcutaneous semaglutide efficacy and safety in type 2 diabetes versus placebo and active comparators (SUSTAIN 1, PMID 28110911; SUSTAIN 7 vs dulaglutide, PMID 29397376; cross-program meta-analysis, PMID 30615985). The cardiovascular-outcomes trial in patients with type 2 diabetes established cardiovascular safety with reduction in MACE (PMID 27633186). Appetite and food-preference effects supporting the obesity indication were characterised in the Blundell work (PMID 28266779) and the STEP program in obesity without diabetes (PMID 33567185, PMID 33667417, PMID 32441473). The SELECT trial extended the cardiovascular-outcomes framing into obesity without diabetes (PMID 37952131, PMID 38740993).
Mechanistic and safety reviews consolidate the dataset across formulations (PMID 34248838), safety profile (PMID 34305810), and effects on lean mass (PMID 38629387). Central-nervous-system distributed neural pathways mediating the weight-loss effect were characterised in the Gabery rodent work (PMID 32213703).
Related terms
- GLP-1 (glucagon-like peptide 1)
- GLP-1 receptor agonist
- Dipeptidyl peptidase IV (DPP-IV)
- Incretin hormone
- Aminoisobutyric acid (Aib)
- Albumin-binding sidechain
Where semaglutide appears in the Ronin catalog
- Semaglutide 10mg — single-compound vial, lyophilized white powder under inert gas; research use only
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19(9):1242-1251. [PMID 28266779]
- Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol 2018;6(4):275-286. [PMID 29397376]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232. [PMID 37952131]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semaglutide is sold strictly as a research-grade reagent for laboratory and bench research applications.